Le Lézard
Classified in: Health, Science and technology, Business
Subject: EARNINGS

PURE Bioscience Reports Fiscal 2023 Financial Results


PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023.

Summary of Results ? Year-End Operations

Business Update

Customer acceptance of our revolutionary SDC solutions in the food processing industry has increased dramatically over the last year, due in part to following reasons:

Robert Bartlett, Chief Executive Officer and President, said, "Our customer driven focus is beginning to pay off. Q4 revenue increased both versus the prior year, as well as our previous quarter. Pure's overall ending revenue for fiscal year 2023 showed a slight increase over fiscal year 2022, and while not substantial on its own, it is important to note that Q4 revenue 2023 vs. Q4 revenue 2022 experienced a 49% increase. A quarter does not make a year, but I see this increase as a turning point and confirmation of our team's implementation of ?new customer driven programs.' These programs were initiated during the Q3 and Q4 of fiscal year 2023. With that said, the Team's focus and continuation of these programs is paramount to our future success," concluded Bartlett.

All-remote Work Environment

Since 2019, when PURE closed its El Cajon offices / warehouse facility, the Company moved almost entirely to a work-from-home model with a few people working at the underutilized corporate office / warehouse location in Rancho Cucamonga. Over the course of FYQ4, PURE has relocated all remaining assets held at the Rancho Cucamonga location to new third-partly facilities throughout the United States. This decision was made, in part, to better service our customers by reducing lead times and costs associated with logistics and for the following key points:

"When the pandemic forced people to stay at home, our remote workforce was already prepared to manage our customers' needs without having to scramble to develop remote workflows. Our success during this demanding time led us to evaluate the benefits of a virtual workplace as a long-term model. We believe having employees working all-remote directly supports our vision as we design the future of PURE. We will continue to evaluate and align the needs of our business and evolve with our workforce to better serve our customer needs," said Jeff Kitchell, VP of Operations and Corporate Secretary.

About PURE Bioscience, Inc.

PURE is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena. We provide solutions to combat the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This is a broad-spectrum, non-toxic antimicrobial agent, and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and mitigation of bacterial resistance. PURE's mailing address located in El Cajon, California (San Diego County area) serves as its official address for all business requirements. Additional information on PURE is available at www.purebio.com.

Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company's expectations, plans, business outlook, future performance, future potential revenues, expected results of the Company's marketing efforts, the execution of contracts under negotiation and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company's ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company's products; the Company's ability to maintain relationships with its partners and other counterparties; the Company's ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company's ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company's SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2023. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

PURE Bioscience, Inc.

Consolidated Balance Sheets

 

 

July 31, 2023

July 31, 2022

Assets

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash and cash equivalents

$

1,095,000

 

$

3,391,000

 

Accounts receivable

 

285,000

 

 

201,000

 

Inventories, net

 

88,000

 

 

179,000

 

Restricted cash

 

75,000

 

 

75,000

 

Prepaid expenses

 

61,000

 

 

18,000

 

Total current assets

 

1,604,000

 

 

3,864,000

 

Property, plant and equipment, net

 

221,000

 

 

620,000

 

Total assets

$

1,825,000

 

$

4,484,000

 

Liabilities and stockholders' equity

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Accounts payable

$

422,000

 

$

488,000

 

Accrued liabilities

 

110,000

 

 

87,000

 

Total current liabilities

 

532,000

 

 

575,000

 

Long-term liabilities

 

 

 

 

 

 

Note payable to related parties

 

1,021,000

 

 

?

 

Total long-term liabilities

 

1,021,000

 

 

?

 

Total liabilities

 

1,553,000

 

 

575,000

 

Commitments and contingencies

 

 

 

 

Stockholders' equity

 

 

 

 

 

 

Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding

 

?

 

 

?

 

Common stock, $0.01 par value: 150,000,000 shares authorized, 111,856,473 shares issued and outstanding at July 31, 2023, and 111,356,473 shares issued and outstanding at July 31, 2022

 

1,119,000

 

 

1,114,000

 

Additional paid-in capital

 

132,398,000

 

 

132,079,000

 

Accumulated deficit

 

(133,245,000

)

 

(129,284,000

)

Total stockholders' equity

 

272,000

 

 

3,909,000

 

Total liabilities and stockholders' equity

$

1,825,000

 

$

4,484,000

 

PURE Bioscience, Inc.

Consolidated Statements of Operations

 

 

Year ended

 

July 31,

 

2023

2022

Net product sales

$

1,871,000

 

$

1,813,000

 

Royalty revenue

 

6,000

 

 

40,000

 

Total revenue

 

1,877,000

 

 

1,853,000

 

Cost of goods sold

 

906,000

 

 

853,000

 

Gross Profit

 

971,000

 

 

1,000,000

 

Operating costs and expenses

 

 

 

 

 

 

Selling, general and administrative

 

4,302,000

 

 

4,051,000

 

Research and development

 

297,000

 

 

319,000

 

Impairment of fixed assets

 

315,000

 

 

55,000

 

Impairment of intangibles

 

?

 

 

299,000

 

Total operating costs and expenses

 

4,914,000

 

 

4,724,000

 

Loss from operations

 

(3,943,000

)

 

(3,724,000

)

Other income (expense)

 

 

 

 

 

 

Interest expense, net

 

(14,000

)

 

(6,000

)

Other income (expense), net

 

(4,000

)

 

?

 

Gain on extinguishment of indebtedness, net

 

?

 

 

239,000

 

Total other income (expense)

 

(18,000

)

 

233,000

 

Net loss

$

(3,961,000

)

$

(3,491,000

)

Basic and diluted net loss per share

$

(0.04

)

$

(0.04

)

Shares used in computing basic and diluted net loss per share

 

111,404,418

 

 

88,835,424

 

PURE Bioscience, Inc.

Consolidated Statements of Stockholders' Equity

 

 

Common Stock

Additional
Paid-In

Accumulated

Total
Stockholders'

 

Shares

Amount

Capital

Deficit

Equity

Balance July 31, 2021

87,223,141

$

873,000

$

128,253,000

 

$

(125,793,000

)

$

3,333,000

 

Issuance of common stock in private placements to related parties, net

23,333,332

 

233,000

 

3,267,000

 

 

 

 

 

3,500,000

 

Share-based compensation expense - stock options

?

 

?

 

465,000

 

 

?

 

 

465,000

 

Share-based compensation expense - restricted stock units

?

 

?

 

102,000

 

 

?

 

 

102,000

 

Issuance of common stock for vested restricted stock units

800,000

 

8,000

 

(8,000

)

 

?

 

 

?

 

Net loss

?

 

?

 

?

 

 

(3,491,000

)

 

(3,491,000

)

Balance July 31, 2022

111,356,473

$

1,114,000

$

132,079,000

 

$

(129,284,000

)

$

3,909,000

 

Balance

111,356,473

$

1,114,000

$

132,079,000

$

(129,284,000

)

$

3,909,000

Share-based compensation expense - stock options

?

 

?

 

262,000

 

 

?

 

 

262,000

 

Share-based compensation expense - restricted stock units

?

 

?

 

62,000

 

 

?

 

 

62,000

 

Issuance of common stock for vested restricted stock units

500,000

 

5,000

 

(5,000

)

 

?

 

 

?

 

Net loss

?

 

?

 

?

 

 

(3,961,000

)

 

(3,961,000

)

Balance July 31, 2023

111,856,473

$

1,119,000

$

132,398,000

 

$

(133,245,000

)

$

272,000

 

PURE Bioscience, Inc.

Consolidated Statements of Cash Flows

 

 

Year Ended

 

July 31,

 

2023

2022

Operating activities

 

 

 

 

 

 

Net loss

$

(3,961,000

)

$

(3,491,000

)

Adjustments to reconcile loss to net cash used in operating activities:

 

 

 

 

 

 

Share-based compensation

 

324,000

 

 

567,000

 

Impairment of fixed assets

 

315,000

 

 

55,000

 

Depreciation and amortization

 

117,000

 

 

213,000

 

Reserve for inventory obsolescence

 

34,000

 

 

75,000

 

Impairment of intangibles

 

?

 

 

299,000

 

Gain on extinguishment of indebtedness

 

?

 

 

(239,000

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

(84,000

)

 

167,000

 

Inventories

 

57,000

 

 

78,000

 

Prepaid expenses

 

(43,000

)

 

14,000

 

Accounts payable and accrued liabilities

 

(43,000

)

 

(156,000

)

Interest on note payable

 

6,000

 

 

?

 

Net cash used in operating activities

 

(3,278,000

)

 

(2,418,000

)

Investing activities

 

 

 

 

 

 

Purchases of property, plant and equipment

 

(33,000

)

 

(81,000

)

Net cash used in investing activities

 

(33,000

)

 

(81,000

)

Financing activities

 

 

 

 

 

 

Net proceeds from note payable to related parties

 

1,015,000

 

 

?

 

Net proceeds from the sale of common stock

 

?

 

 

3,500,000

 

Net cash provided by financing activities

 

1,015,000

 

 

3,500,000

 

Net (decrease) and increase in cash, cash equivalents, and restricted cash

 

(2,296,000

)

 

1,001,000

 

Cash, cash equivalents, and restricted cash at beginning of year

 

3,466,000

 

 

2,465,000

 

Cash, cash equivalents, and restricted cash at end of year

$

1,170,000

 

$

3,466,000

 

 

 

 

 

 

 

 

Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets

 

 

 

 

 

 

Cash and cash equivalents

$

1,095,000

 

$

3,391,000

 

Restricted cash

 

75,000

 

 

75,000

 

Total cash, cash equivalents and restricted cash

$

1,170,000

 

$

3,466,000

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

Cash paid for taxes

$

5,000

 

$

2,000

 

 


These press releases may also interest you

at 06:30
Voyageur Mineral Explorers Corp. ("Voyageur" or the "Company") is pleased to announce that is has entered into an option agreement (the "Option") with Callinex Mines Inc. ("Callinex"), whereby Callinex may acquire a 100% interest in the Company's...

at 06:30
CGI , one of the largest independent IT and business consulting services firms in the world, has been selected by the UK Government's Home Office as the Technology Delivery Partner for the Emergency Services Mobile Communications Programme (ESMCP)...

at 06:30
PermRock Royalty Trust (the "Trust") today declared a monthly cash distribution to record holders of its trust units representing beneficial interests in the Trust ("Trust Units") as of May 31, 2024, and payable on June 14, 2024, in the amount of...

at 06:30
Highlights: Acquired and staked ground consolidates the largest felsic volcanic rock package in the Flin Flon Greenstone Belt, the host rock for the majority of the historic copper/gold/zinc/silver VMS mines in the Flin Flon and Snow Lake...

at 06:16
Aramco, one of the world's leading integrated energy and chemicals companies, has signed an agreement with Pasqal, a global leader in neutral atom quantum computing, to install the first quantum computer in the Kingdom of Saudi Arabia. The agreement...

at 06:09
Béné Tipping, the premier digital tipping platform for hospitality service providers, announced the launch of a first-of-its-kind cashless tipping platform that allows employers and customers to team up on tipping. This unique feature fixes the...



News published on and distributed by: